CC
AMLX icon

Centiva Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Centiva Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-45,464
Closed -$291K – 1073
2025
Q2 		$291K Buy
45,464
+17,242
+61% +$83.9K ﹤0.01% 1201
2025
Q1 		$99.9K Sell
28,222
-5,609
-17% -$20K ﹤0.01% 1398
2024
Q4 		$128K Buy
+33,831
New +$159K ﹤0.01% 1455
2024
Q3 		– Sell
-90,733
Closed -$172K – 2102
2024
Q2 		$172K Buy
+90,733
New +$176K ﹤0.01% 1730
2024
Q1 		– Sell
-19,188
Closed -$282K – 1740
2023
Q4 		$282K Buy
+19,188
New +$294K 0.01% 1234

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Centiva Capital's AMLX Position: Q3 2025 in Review

Centiva Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 45,464 shares — an estimated $291K sold.

Centiva Capital first reported a position in AMLX in Q4 2023 and held it in 5 quarters. The position peaked at $291K in Q2 2025. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

  • Centiva Capital reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Centiva Capital sold 45,464 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $291K.
  • Centiva Capital first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 5 quarters.
  • Centiva Capital's Amylyx Pharmaceuticals position peaked at $291K in Q2 2025.
  • 169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Centiva Capital's 13F filing for Q3 2025, filed 14 Nov 2025.